#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating multiple sclerosis patients with spasticity now have emerging evidence supporting cannabis-based therapies as a potential adjunctive option when conventional treatments are inadequate or poorly tolerated. Understanding the efficacy and safety profile of cannabinoids like nabiximols enables informed shared decision-making with patients about realistic benefits and risks. This evidence helps clinicians address a common, debilitating MS symptom where treatment options are limited, potentially improving functional outcomes and quality of life.
A systematic review of cannabinoid therapies for multiple sclerosis-related spasticity found that THC and CBD formulations, particularly nabiximols (a standardized 1:1 THC:CBD oral spray), demonstrated modest but consistent efficacy in reducing muscle tone and spasticity symptoms compared to placebo. The evidence base, while positive, reflects small to moderate effect sizes with relatively short treatment durations in most trials, suggesting cannabinoids may be considered as adjunctive rather than first-line agents for MS spasticity management. Safety profiles were generally favorable in the reviewed studies, though common side effects including dizziness, drowsiness, and cognitive effects warrant careful patient counseling and monitoring, particularly in patients already on multiple medications. The clinical implication is that cannabis-based therapies, especially those with defined THC:CBD ratios and pharmaceutical standardization, may offer a treatment option for MS patients with spasticity who have inadequate response to or intolerance of conventional antispasticity agents. Clinicians considering cannabinoid therapy for this indication should document baseline spasticity severity, establish clear functional goals with patients, and monitor for both therapeutic response and adverse effects. For patients and providers, this evidence supports cautious consideration of standardized cannabinoid formulations for MS spasticity, but robust clinical trials with longer follow-up periods are needed to establish optimal dosing, duration, and patient selection criteria.
“We do have peer-reviewed evidence from clinical trials showing that nabiximols can produce modest reductions in spasticity for some MS patients, which is clinically meaningful when other options have failed, though the effect sizes are modest and individual responses vary considerably.”
💊 While cannabinoid-based therapies, particularly nabiximols (a THC/CBD combination), demonstrate modest efficacy for spasticity in multiple sclerosis patients, clinicians should recognize that effect sizes are generally small and individual responses vary considerably. The evidence base remains limited by short study durations, small sample sizes, and publication bias, making it difficult to predict which MS patients will benefit most or to compare efficacy reliably against established antispasticity agents like baclofen or tizanidine. Important confounders include concurrent disease-modifying therapies, disease stage heterogeneity, and the challenge of blinding in cannabis trials, all of which complicate interpretation of comparative effectiveness. Additionally, regulatory status, cost, and local legal frameworks create practical barriers to access that may limit real-world applicability regardless of efficacy. Given these limitations, cannabinoid therapies might reasonably be considered for MS-related sp
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
